Partner, Novo Holdings
Nanna joined Novo Holdings in 2012, and spent four years as part of Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards as Director or Observer at Inthera, IO Biotech, MinervaX, Pcovery, Forendo and Galecto. Nanna joined Novo Ventures in 2016, and has been involved in both private and public investments, including successful public listings of Orphazyme (ORPHA) and ObsEva (OBSV), and currently serves on the boards of Epsilon-3 Bio and Stargazer Pharmaceuticals.
Prior to her time at Novo Holdings, Nanna was part of the life science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund, including Convergence, Ulthera and Cancer Partners UK. She also has experience from Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford.